No category found.

  • To share data with anyone who asks.
  • To urgently implement robust data anonymization, security protocols, and obtain appropriate ethical approvals to protect patient privacy and confidentiality.
  • To collect as much data as possible without consent.
  • To only focus on statistical analysis.
  • To immediately implement the program.
  • To urgently explain that for rare diseases, a high positive predictive value (PPV) is difficult to achieve, leading to unnecessary anxiety and follow-up for many healthy individuals.
  • To ignore the concept of false positives.
  • To use a less sensitive test.
  • To immediately adopt the new therapy.
  • To urgently advise that conclusions should not be based on a single study, especially close to the significance threshold, and that replication and meta-analysis are critically important.
  • To ignore all p-values.
  • To assume one study is enough.
  • To proceed with the trial as is.
  • To urgently recommend revising or replacing the outcome measure to ensure reliable and valid data collection, crucial for the integrity of the results.
  • To ignore measurement issues.
  • To tell the clinicians to be more careful.
Scroll to Top